During the use of avatranib, special attention should be paid to the risk of thrombosis, hepatotoxicity, and drug interactions to ensure medication safety.

1、 Thrombosis risk and prevention

Identify potential risks

Avatranib may increase the risk of thrombosis, especially in patients with a history of thrombosis or hypercoagulability. If symptoms such as chest pain, lower limb swelling, and difficulty breathing occur, seek medical attention immediately.

Regularly monitor platelets

Excessive platelet count may exacerbate the risk of thrombosis. During treatment, regular check ups should be conducted according to medical advice to avoid platelet count exceeding the target range.

Maintain activity and hydration

Avoid prolonged bed rest and engage in appropriate activities to promote blood circulation. Drink plenty of water daily to prevent an increase in blood viscosity.

2、 Key points for liver toxicity monitoring

Pre medication screening for liver function

Before starting treatment, baseline liver function (ALT, AST, bilirubin, etc.) should be tested to ensure that the liver condition is suitable for medication.

Regular follow-up during treatment

Long term medication users need to undergo regular liver function check ups. If there is fatigue, decreased appetite, yellowing of the skin and sclera, or darkening of urine color, the doctor should be informed in a timely manner.

Use with caution in patients with severe liver disease

Patients with moderate to severe liver dysfunction should adjust the dosage or avoid use under the guidance of a doctor to prevent drug accumulation from exacerbating liver damage.

3、 Common drug interactions

Avoid co use with CYP2C9 substrates

Avatranib may affect the CYP2C9 metabolic pathway. When used in combination with warfarin, phenytoin, etc., the efficacy and adverse reactions should be closely monitored.

Cautiously combining anticoagulant/antiplatelet drugs

When used in combination with anticoagulants (such as warfarin) or antiplatelet drugs (such as aspirin), there may be an increased risk of bleeding or thrombosis, which requires individualized evaluation.

Pay attention to the effects of proton pump inhibitors (PPIs)

PPI drugs may reduce the absorption of atorvastatin. It is recommended to stagger the medication time or choose H2 receptor antagonists as substitutes.